SmartManage for the Reduction of Symptom Burden in HIV+ Gay and Bisexual Men Treated for Non-Metastatic Cancer

Inclusion Criteria

• Be >= 18 years of age
• Be fluent in English
• Have evidence of at least one form of non-metastatic solid tumor cancer, including, but not limited to, the following types: * Oral cavity and pharynx (i.e. tongue, mouth, pharynx, etc.) * Digestive system (i.e. esophagus, stomach, small intestine, colon, etc.) * Respiratory system (i.e. larynx, lung, bronchus, etc.) * Urinary system (i.e. kidneys, bladder, urethra, ureters) * Bone and joint * Soft tissue (including heart) * Breast (male) * Genital system (male, i.e. prostate, testis, penis, etc.) * Endocrine (i.e. thyroid, adrenal glands, pancreas, etc.) * Melanoma skin cancer * Leukemia (or other cancers of the blood)
• Be >= 30 days post active primary treatment (i.e. surgery, radiation, and/or chemotherapy) for their cancer. (Note: Primary treatment may be determined based on the type of cancer the participant has had and may be subject to principal investigator [PI] review on a case-by-case basis. Adjuvant therapies, such as hormone therapy for prostate cancer, etc. are not considered exclusionary) * Participants enrolled in the usability-testing phase of the study will not be eligible to participate in the randomized trial
• Self-identify as a sexual minority, cisgender man (self-identify as something other than heterosexual or straight, assigned male at birth and identify as male)
• Self-report having been diagnosed with HIV
• Have reliable access to a computer/device with internet accessibility (only applicable to those individuals participating in the field-testing phase of the pilot)

Exclusion Criteria

• Have had one of the following exclusionary cancer types: * Non-melanoma skin cancer only (not in combination with another type listed in the inclusion criteria above) * Brain cancer * Eye cancer * History of some form of pediatric cancer (if the pediatric cancer is the only cancer diagnosis the patient has had)
• Have a history of advanced (metastatic) cancer of any type
• Currently be undergoing primary treatment for their cancer
• Have had inpatient treatment for severe mental illness in the past 12 months or have overt signs of psychopathology (i.e. psychosis) and/or suicidality deemed moderate or greater risk at the time of screening. Appears actively showing signs of psychopathology or otherwise unable to provide full informed consent at the time of screening
• Appears actively intoxicated or otherwise unable to provide full informed consent at the time of screening
• Have any other medical conditions resulting in a predicted life expectancy < 12 months